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1. Introduction 
Regenerative tissue engineering is defined as the combination of living cells and biocompatible 
scaffolds to generate a biologic substitute capable of sustaining itself and integrating with 
functional native tissue. By engineering and delivering tissues and/ or cells capable of 
replacing damaged tissue, regenerative medicine offers the potential for the treatment and 
possibly curing of debilitating diseases. Optimized methods for improving the function and 
maturation of engineered cellular constructs to produce constructs with near-native tissue 
properties are necessary to enable translation to clinically useful therapies.  
In regenerative tissue engineering, there are many issues to consider in the creation of a 
functional, implantable replacement tissue. Most importantly, there must be an easily 
accessible, readily abundant cell source with the capacity to express the desired tissues’ 
phenotype, and a biocompatible inert scaffold to deliver the cells to the damaged region. 
Currently, there are many regenerative tissue engineering studies in preclinical and clinical 
testing using stem cells. 
What are stem cells? In the body there are many different types of cells, each specialized for a 
specific distinct function. These cells are committed to a specific lineage and function, for 
example cardiomyocytes in the heart, chondrocytes in cartilage, and osteoblasts in bone. 
Immature progenitor cells called stem cells are not lineage specific. Stem cells have the ability 
to differentiate into many different kinds of cells. Differentiation is the process by which an 
unspecialized parent or progenitor cell gives rise to a specialized daughter cell; this process 
occurs in stages with the cell becoming increasingly specialized with each step. At 
fertilization, a zygote is formed containing totipotent stem cells which can differentiate into 
any cell type. After a few days, the blastocyst develops with an outer layer and inner cell 
mass. Cells from the inner cell mass are pluripotent stem cells and can become cells from all of 
the germ layers (ectoderm, mesoderm, endoderm). As the embryo continues to develop, the 
cells become increasingly specialized and begin to commit to specific cell lineages (as seen in 
Figure 1 below). Cells committed to a specific cell type and function lose their stemness; 
however, a population of undifferentiated stem cells remains amongst the differentiated cells. 
These adult stem cells can be harvested from various tissues in the body and then cultured in-
vitro. Under specific culture conditions, those undifferentiated cells can be directed towards 
specific lineages, providing us with a potentially limitless supply of tissue. 
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Fig. 1. Stem cell differentiation diagram 
There are two parameters used to assess the tissue engineering potential of stem cells: 
proliferation rate and differentiation potential. The cells’ proliferation rate is the speed at 
which the cells divide. The cell differentiation potential determines whether the cell line is 
capable of developing into specific lineages, in this case osteogenic. These components are 
critical, because if cells are not expanding at a specific rate and are not differentiating 
towards the lineage desired, the engineered tissue will not mirror the characteristics of 
native tissue and serve the desired function.  
2. Bone properties 
2.1 Bone composition 
Bone is a multifunctional organ that plays many important roles in the body, such as 
providing protection and structure (shape) among others. Despite its relatively simple outer 
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appearance, bone is not a solid homogenous tissue. Bone is made up of solid material with 
spaces between its hard elements. The outer smooth portion of the bone is compact or 
cortical bone (80% of bone), and the inner spongy part of the bone is trabecular bone (20% of 
bone). Furthermore, within those regions are different types of cells making up the cellular 
structure of the bone itself: osteoblasts, osteocytes, and osteoclasts. Osteoblasts are bone 
forming cells and are the direct descendants of osteoprogenitor cells (Kneser et al., 2006; 
Buckwalter & Hunziker, 1996; Heinegard & Oldberg, 1989). They produce a protein mixture 
called osteoid which mineralizes to form solid bone, and produce alkaline phosphatase 
(ALP), a key enzyme in bone mineralization. Osteocytes are descendants of osteoblasts 
which migrate into the bone matrix forming lacunae spaces. Osteocytes are responsible for 
bone formation, matrix maintenance, and calcium homeostasis. Osteoclasts are the bone’s 
absorption cells. These are the cells that are responsible for bone remodeling and the overall 
decrease in bone mineral density (Shier et al., 2002). Bone is a connective tissue which 
provides structural support and protects the vital organs while allowing for movement. 
Bone is composed of a type I collagen matrix embedded with calcium, phosphorous, 
sodium, magnesium and other ions necessary for homeostasis in the body. The extracellular 
components of bone (organic matrix and minerals) combine to strengthen the bone, giving it 
the ability to withstand mechanical stresses.  
2.2 Bone formation and maturation in vivo 
Within the body there are two main mechanisms of bone formation and growth, 
intramembranous ossification for flat bones and endochondral ossification for long bones. In 
intramembranous ossification, connective tissue occupies the place of the future bone and is 
slowly replaced as ossification centers develop, calcification occurs, and the trabeculae 
forms. In endochondral ossification, also referred to as intracartilaginous ossification, a 
cartilage model template structure is used on which the primary and secondary ossification 
centers are established. When bone is finished forming, remnant articular cartilage often 
remains on the end of the bones. Although induced tissue engineering differs from either 
pathway, in vitro osteogenic differentiation more accurately mirrors the intramembranous 
ossification process.  
2.3 Bone repair 
Following injury, a healing cascade is triggered to restore the tissue’s original state. This 
healing cascade occurs in three phases: inflammatory, repair, and remodeling (as seen in 
Figure 2). Briefly, the inflammatory phase results in hematoma formation as fibroblasts and 
cells from the inflammatory cascade (macrophages, monocytes, lymphocytes etc.) migrate 
into the injury site (hours to days). In the repair phase, collagen fibers and mineralized 
osteoid combine to form a soft callus around the injury site (4-6 weeks). As the callus ossifies 
it forms a disorganized structure known as woven bone. During the remodeling phase the 
disorganized woven bone is replaced by highly organized sheets of parallel collagen fibers 
called lamellar bone. This restructuring occurs in response to mechanical stresses signaled to 
the osteocytes and subsequently osteoclasts and osteoblasts (Kneser et al., 2006; Probst & 
Spiegel, 1997). The repair mechanism continues to change the bone properties through 
constant remodeling via bone deposition and resorption (Kneser et al., 2006; Kalfas, 2001). 
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Bone tissue can be damaged due to injury or disease. Following a traumatic event, fractured 
bones can be aligned by a physician, and the damaged area can heal and repair. However, 
bones that are damaged due to disease are not as successful at self-restoration as bones set 
by a physician and do not have the ability to repair and remodel properly.  
 
 
 
Fig. 2. Bone repair mechanism 
2.4 Current treatments for damaged bone 
2.4.1 Bone grafts 
Bone grafts are used to enhance bone healing in specific injury zones. There are a number 
of factors to take into consideration when selecting a bone graft, such as 
osteoinductiveness, osteoconductiveness, mechanical stability, quality of transplantable 
bone, and preservation techniques, as well as implantation site considerations such as 
local disease and biomechanical properties (Khan, et al., 2005). Osteoconductive grafts 
function as a scaffold for native bone cells adjacent to the graft to migrate into and form 
new bone. Osteoinductive grafts serve to actively stimulate progenitor cells to 
differentiate into osteoblasts. A graft can be considered osteogenic if it already contains 
osteoblasts. The main types of grafts currently being utilized are autografts, allografts, 
xenografts, and synthetic grafts.  
Conventionally, autografts are the most effective grafts since they are harvested from the 
patient’s own body, usually from the iliac crest, fibula, ribs, or mandible. Although using 
the patient’s own bone reduces the risk of rejection and disease transfer, it also increases 
pain, since the donor graft must be harvested surgically. In addition to the risk of infection 
from harvesting the patient’s own bone, the process can be extremely painful, and as with 
all surgeries, there is always the risk of complications. Autografts are osteoconductive, 
osteoinductive, and osteogenic, which is what makes them the ideal choice (Burchardt, 
1983). However, the amount of bone available for autografts is limited and the procedure 
creates a secondary healing site. 
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Allografts, on the other hand, are also natural human bone grafts, but unlike autografts 
which are harvested from the patient’s own body, allografts are harvested from an external 
donor. Although the allograft eliminates the need for an additional surgery on the recipient, 
they also do not have the immunogenic properties of the autograft, and the risk of rejection 
increases (Mankin et al., 2005). Depending on how the allograft was harvested, stored, and 
treated, it will have osteoconductive properties, but may or may not have osteoinductive 
properties, and will not have any osteogenic properties (Mankin et al., 2005). For example, 
freeze-drying samples reduces antigenicity while maintaining biomechanical properties. 
Xenografts are grafts that are harvested from another species and are stripped down to just 
their calcium matrix. These grafts are osteoconductive but not osteoinductive or osteogenic. 
Due to their limited surface properties, synthetic grafts are a preferred alternative.  
Synthetic grafts are artificial bone grafts that can be made of biologically active materials such 
as ceramics, bioglasses, or even calcium sulphate. These grafts can be functionalized with 
growth factors to increase their osteoconductive and osteoinductive abilities. Along those 
lines, engineering a replacement bone tissue from the patients’ own autologous stem cells 
seems to be a more practical solution. An explanation of various biomaterials that are used to 
make synthetic grafts will be explained later in the scaffolds section of the chapter (Section 5). 
2.4.2 Bone bracing 
In some cases damaged bones are incapable of properly repairing and remodelling; 
therefore, additional steps such as utilizing bone bracing can be taken to aid the 
reconstruction. These approaches include both surgical and non-surgical methods of 
immobilizing the injured region allowing bone repair to begin.  
Non-surgical alternatives such as external casts and bracing are viable alternatives in cases 
with fracture displacements less than 2mm. This is the preferable method for bone healing, 
as it is non-invasive and minimizes risk of infection. Regenerative tissue engineering is not 
required in these cases and may not be applicable for these cases.  
Surgical approaches, such as open reduction internal fixation in which bones are set and 
held in place by nails, screws, or plates to guide and facilitate the healing process. 
Unfortunately, as with an surgical option, there is an increased risk of infection; however, 
surgical approaches are necessary in fracture displacements exceeding 2mm. In cases where 
surgery is required, regenerative tissue engineering may provide the materials necessary for 
creating bone in these voids, reducing healing time and increasing bone strength. Usually 
these fixation devices are metals, which provide immediate mechanical support; however, 
metals have poor integration into the bone and can cause re-injury and implant failure over 
time, therefore, alternative approaches are being investigated. 
2.4.3 Biomaterials and alternative approaches 
In some cases, bones that are damaged are unable to repair and remodel properly and 
additional steps can be taken to aid the reconstruction, such as utilizing bone cements. In 
other cases, joint replacement surgery is needed to repair areas where the cartilage has been 
destroyed and the bones are exposed. When this occurs, a prosthetic joint is drilled into the 
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bone and can either be cemented in with a polymer bone cement or left un-cemented. 
Traditionally, acrylate-based bone cements have been used for their high mechanical 
stability (Muh, et al., 2002; Lewis, 1997). When the bone is cemented in place, the recovery 
time is much quicker than when left un-cemented. On the other hand, when left un-
cemented, the natural bone can grow into the porous surfaces of the implant, making it 
stronger over time. This means that the implant is less likely to fail, which would require an 
additional surgery. Therefore, osteoinductive alternative, such as calcium phosphate and 
apatite-based bone cements, have been investigated. Although osteoinductivity is increased, 
these cements are also biodegradable, therefore, their mechanical strength decreases over 
time (Cassidy, et al., 2003; Zijderveld et al., 2005).  
In regenerative tissue engineering, living cells and biocompatible scaffolds are combined 
to generate biologic substitutes capable of sustaining themselves and mimicking 
functional native bone. This is accomplished by incorporating osteoinductive and 
osteoconductive molecules into the scaffold, as explained in the scaffolds section of the 
chapter (Section 5). 
3. Bone tissue engineering with stem cells 
Cells are the basic functional and structural unit in the body. All cells in the body have the 
same primary DNA sequence; however, changes in phenotypic expression result in cells 
with a variety of shapes and sizes which correlate to the function of each cell. This diversity 
comes at a cost; in general, once a cell has differentiated into a specific lineage, it cannot 
revert back to its primordial state (exceptions, ex: cancer and induced pluripotent stem 
cells). Stem cells, however, are undifferentiated cells (a characteristic referred to as 
stemness). These cells have not committed to any specific lineage and can give rise to a 
variety of specialized cell types depending on their plasticity. A cell’s plasticity is its ability 
or inability to differentiate into any of the germ layers (ectoderm, mesoderm, endoderm) 
based on culture conditions. 
In general, differentiated cells have a limited number of population doublings over the 
course of a person’s life (approximately 80-90 times) (Fox, 2001). During telophase of 
mitosis, the telomere region of the chromosomes lose some of the DNA sequences, 
approximately 50-100 base pairs (Fox, 2001). Stem cells (as well as germinal cells and cancer 
cells) produce telomerase, an enzyme which duplicates the telomere DNA; therefore, stem 
cells are capable of dividing and self-renewal for long periods of time and are often referred 
to as immortal. Furthermore, when stem cells divide, they can undergo either symmetric 
division, producing two daughter stem cells identical to the parent cell, or by asymmetric 
division, producing one daughter stem cell and one daughter progenitor cell. 
Stem cell biology has become an important topic in regenerative tissue engineering, 
specifically the use of multipotent mesenchymal stem cells (MSCs). Although embryonic 
stem cells are considered the gold standard in stem cell research, bone-marrow derived 
mesenchymal stem cells (BM-MSCs) are the most researched postnatal stem cells. 
Multipotent postnatal stem cells have been isolated from numerous tissues throughout the 
body such as bone marrow, adipose tissue, muscle, dental tissue, umbilical cord, etc. 
(Campagnoli et al., 2001; Zuk et al., 2001; Gronthos et al., 2000; Miura, et al., 2003; Seo, et al., 
2004; Schugar, et al., 2009; Young, et al., 2001).These stem cells are capable of differentiating 
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into a variety of cell lineages, including bone. Therefore, transplanting a patient’s own stem 
cells may be a potential treatment for repairing bone defects. This chapter details progress 
made to date in the osteogenic differentiation potential of these cell lines and their potential 
use in repairing bone defects. 
3.1 Embryonic stem cells 
At fertilization, a zygote is formed that contains totipotent cells which are cells with the 
ability to form any of the 200+ cell types in the body and the cells of the placenta. After four 
days (about 40-150 cells), the blastocyst develops. The blastocyst is identifiable by the 
development of the outer trophoblastic layer and inner cell mass (ICM). The outer layer of 
cells becomes the placenta and other tissues necessary for fetal development and survival. 
The inner cell mass forms the fetus and contains pluripotent cells that go on to form all the 
tissues in the human body. The use of pluripotent embryonic stem cells in regenerative 
therapies is an attractive option with the ability to give rise to tissues from the three germ 
layers, including the mesodermal lineages such as bone. 
Both totipotent and pluripotent (blastocyst) embryonic stem cells (ESCs) (Figure 1) are 
considered the gold standard in stem cells; however, controversy and debate surround 
ESCs. Despite the ethical debate, clinical benefits from ESCs could be numerous, but more 
work is needed before they can be used for clinical applications. In addition to the ethical 
considerations, additional concerns for using ESCs include the potential for teratoma 
formation when implanted in vivo.  
3.1.1 Fetal stem cells 
Fetal stem cells are cells obtained from an unborn fetus when the fetus has developed 
enough that cellular extraction does not cause fetal death. These cells are pluripotent and 
responsible for the development of all tissues before birth. Unlike ESCs, fetal stem cells can 
be obtained without completely destroying the embryo, allowing the fetus to develop into a 
full-term baby (Biswas & Hutchins, 2007). However, the effect of removing cells during fetal 
development is unknown, and fetal stem cells have many of the same ethical considerations 
as ESCs. These pluripotent cells can undergo osteogenic differentiation, making them a 
valid source for regenerative bone tissue engineering. 
3.2 Bone marrow-derived mesenchymal stem cells 
BM-MSCs are a heterogeneous population of multipotent cells. BM-MSCs are capable of 
differentiating into multiple lineages in vitro including the osteogenic lineage. BM-MSCs are 
a popular source of autologous adult stem cells, because they are readily available. 
However, the extraction procedure is extremely painful and invasive. In addition to their 
differentiation potential, BM-MSCs can be used directly to positively influence the repair 
mechanism and healing of cardiac tissue following a myocardial infarction (Amado, et al., 
2005). Impressively, this is accomplished with BM-MSCs from living donor tissue, and the 
BM-MSCs inherent immunogenic characteristics limit the recipient’s immune response to 
the foreign cells. This makes BM-MSCs a great source for regenerative tissue engineering 
applications, because they can be extracted, expanded, and banked, making them readily 
available when they are needed. 
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3.3 Umbilical cord blood stem cells 
Umbilical cord blood (UCB) stem cells are cells found in the umbilical cord blood of a 
newborn baby, and they share the newborn’s genetic material. UCB cells can be obtained 
with higher cell yields and without the pain and morbidity associated with BM-MSC 
acquisition (G. Huang et al., 2009). These cells are multiotent, hematopoietic stem cells and 
can differentiate into various cell lines including the osteogenic lineage (Liu, et al., 2011). In 
addition to their differentiation potential, UCB cells can be used directly to successfully treat 
leukemia, lymphoma, myelodysplasia, apalstic anemia, hemoglobinpathies, metabolic 
diseases, and immunodeficiencies (Brunstein et al., 2007; Ballen, et al., 2008). UCB cells have 
similar morphologic and immunophenotypic properties to BM-MSCs (Kern et al., 2006); 
however, UCBs form fewer colonies than BM-MSCs, and UCB cells form have a high 
proliferative capacity (G. Huang et al., 2009), perhaps due to their age and harvest location. 
Until recently, umbilical cords were discarded at birth, so most individuals have lost their 
source for autologous UCB cells. Now, parents are given the option of donating their 
newborn’s UCB cells to public storage banks or saving them in a private bank for 
autologous or family member use.  
3.4 Stem cells from dental tissues  
Physiological similarities between dental-tissue and bone make dental-derived progenitor 
cells a logical source of stem cells for osteogenic differentiation. Cells from dental tissues are 
called ectomesenchyme cells, because they are remnant tissues derived from the cranial 
neural crest. Cranial neural crest cells are capable of differentiating into bone, cartilage, and 
ligament during embryonic development; therefore, cells derived from them possess similar 
abilities (Chai, et al., 2000; Huysseune & Thesleff, 2004; Le Douarin et al., 2004).  
3.4.1 Stem cells from human exfoliated deciduous teeth  
SHED (stem cells from human exfoliated deciduous teeth) are multipotent stem cells 
isolated from the remnant pulp of deciduous (baby) teeth (Miura, et al., 2003). Similar to the 
umbilical cord, deciduous teeth offer the opportunity for painlessly obtaining primordial 
cells that would otherwise have been thrown away. SHED proliferate faster than BM-MSCs, 
can undergo osteogenic differentiation, and express ESC markers (Kerkis, et al., 2006; Miura, 
et al., 2003). Furthermore, SHED appear to have osteoinductive properties, meaning they 
induce new bone formation by recruiting osteogenic host cells into an osteoinductive 
template (Miura, et al., 2003). This approach is already being used to repair critical-size 
calvarial defects in mice (Seo, et al., 2007). 
3.4.2 Dental pulp stem cells 
Similar to SHED, dental pulp stem cells (DPSCs) are heterogeneous populations of cells 
isolated from the human dental pulp of mature teeth. Within a colony of these multipotent 
cells, various cell morphologies are expressed. DPSCs proliferate faster than BM-MSCs but not 
as fast as SHED (Miura, et al., 2003) and are capable of differentiating into various lineages 
including osteogenic (Laino, et al., 2005). Interestingly, DPSCs cultured on dentin differentiate 
into odontoblast-like cells (Batouli, et al., 2003), suggesting that DPSCs are pre-differentiated 
towards soft tissue repair or even bone tissue interfaces, but not osteogenesis.  
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3.4.3 Periodontal ligament stem cells 
Heterogeneous populations of multipotent stem cells (PDLSCs) have also been extracted 
from the periodontal ligament, a descendant of the cranial neural crest. PDLs express 
several ESC markers and have an upregulated telomerase activity, suggesting similar 
differentiation abilities to ESCs (C. Huang et al., 2009). Similar to other dental tissues, 
PDLSCs are capable of undergoing osteogenic differentiation and express osteogenic 
characteristics (Seo, et al., 2004; Gay et al., 2007; Isaka, et al., 2001; C. Huang et al., 2009). 
Furthermore, PDLSCs that are implanted in periodontal injuries regenerated a periodontal 
ligament-like tissue while aiding in the bone regeneration itself (Seo, et al., 2004). This 
suggests that they would be a viable source for regenerative bone tissue engineering.  
3.5 Adipose tissue-derived stem cells 
Adipose tissue-derived stem cells (ASCs) are multipotent cells located in fat that can 
differentiate into various cell lines including the osteogenic lineage (Levi & Longaker, 2011; 
Wagner, et al., 2005). ASCs can be isolated from the lipoaspirate usually discarded from 
liposuction treatments. ASCs have been shown to not only undergo osteogenesis, but have 
actually been used to heal critical-size defects in mice (Cowan, et al., 2004). Furthermore, 
ASCs promote angiogenesis (new blood vessel formation), which can be crucial for 
engineered scaffolds to properly integrate with native tissue (Schroeder & Mosheiff, 2011; 
Kim Y. , et al., 2007). 
3.6 Induced pluripotent stem cells 
As mentioned before, adult stem cells can be harvested from various tissues in the body and 
then, under specific culture conditions, directed towards specific lineages, thereby 
providing us with a potentially limitless supply of tissue. In general, ESCs are considered to 
be the gold standard in stem cell research due to their true pluripotency, and all other stem 
cells are measured in comparison. However, there are many ethical issues surrounding 
ESCs, most notably their source and the debate of whether or not the method used for the 
isolation of ESCs is murder. These ethical dilemmas and political restrictions on ESC use led 
researchers to investigate methods of reverting differentiated somatic cells back into their 
primordial pluripotent state. These reverted cells are called induced pluripotent stem (iPS) 
cells. 
One of the earliest techniques for creating iPS cells was by retrovirus transduction of specific 
transcription factors to promote ESC-like characteristics and ultimately create a line of 
pluripotent adult stem cells (Yu, et al., 2007; Takahashi, et al., 2007; Takahashi & Yamanaka, 
2006; Meissner et al., 2007; Okita et al., 2007). Once the iPS cells are generated, they are 
evaluated for ESC characteristics by RT-PCR, Western blot, telomerase detection, genomic 
sequencing, and immunohistochemistry. Most retrovirus transduction techniques use 
transcription factors that are naturally found up-regulated in ESCs. Once cells expressing ESC 
characteristics are identified (transcription factor transduction has a relatively low yield), the 
iPS cells’ stemness must be evaluated, and the cells are tested for population clonogenicity, 
immortality, and pluripotency. Clonogenicity and immortality are evaluated by allowing the 
iPS cells to undergo significant population doublings. Next, the cells pluripotency is evaluated 
through in vitro culture and in vivo, and the cells are evaluated on their ability to differentiate 
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into cells representing each of the germ layers. iPS cells represent a unique source for 
pluripotent adult stem cells which can serve as a source for generating patient-specific tissue 
for regenerative tissue engineering applications, such as repairing bone defects. 
Unfortunately, many of the techniques that are used to induce the cells back into the 
pluripotent state have an extremely low yield, making the process both inefficient and 
costly. Furthermore, those same techniques use factors (such as viral vectors to transduce 
genes) which are not FDA approved. With those considerations in mind, research continues 
on traditional stem cells as well as iPS cells. 
3.7 Evaluating potency 
When selecting stem cells for regenerative tissue engineering applications, it is important to 
select cells that are capable of undergoing the necessary differentiation. To evaluate the 
potency of the cells, a variety of tests are performed, and specific factors are identified. 
As mentioned before, telomerase activity in ESCs and some adult stem cells correlates 
with those cells ability to divide indefinitely (Heins, et al., 2004; Biswas & Hutchins, 2007). 
As cells begin to differentiate into specialized cell lines, telomerase levels decrease and 
ultimately disappear. Therefore, the presence of telomerase is a good benchmark for 
evaluating the primordial state of a cell and is often found in cells with the most potency 
potential (totipotent and pluripotent cells) (Heins, et al., 2004; Thomason & Marshall, 
1998a; Biswas & Hutchins, 2007; Odorico et al., 2001). 
Another method of evaluating potency is to allow the cells to grow in culture without 
passaging. When the cells become confluent, contact inhibition allows for spontaneous 
differentiation, and the stem cells will randomly divide into various lineages, thereby 
establishing their ability to form cells from specific germ layers, from which potency can be 
determined (Heins, et al., 2004; Itskovitz-Eldor, et al., 2000). Similarly, cells that are grown in 
3-D cell suspensions form aggregates of differentiated cells called embryoid bodies. 
Continued culture of these embryoid bodies results in the formation of various germ layer 
derivatives (Itskovitz-Eldor, et al., 2000). 
Furthermore, teratoma formation can be used to determine a cell’s potency. Teratoma 
formation occurs when undifferentiated stem cells are injected into severe combined 
immunodeficient (SCID) mice, and the cells form tumors consisting of a variety of cell types 
(Heins, et al., 2004; Thomson, et al., 1998b; Park, et al., 2003; Knoepfler, 2009).  
Finally, specific surface marker expression has been identified for undifferentiated and 
differentiated tissue. Antigen analysis can reveal a cell’s primordial state, suggesting its 
potency (Amit & Itskovitz-Eldor, 2002; Knowles et al., 1978; Biswas & Hutchins, 2007; 
Lebkowski, et al., 2001).  
4. Media formulations for osteogenic differentiation 
All cells in our body contain the exact same DNA sequence of genes; however, the genes 
that are activated depend on the function of each cell. Most cell types have genes that are 
specific to that cell type (due to its unique functionality). These genes are responsible for 
coding specific proteins that are necessary to retain cell function. When cells are changed 
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from stem cells (no specific function) into osteoblasts (cells that make our bones), genes that 
are specific to bone are activated. When a gene is activated, RNA is synthesized 
(transcription), and corresponding proteins are produced (translation). 
In culture, cells can be propagated or differentiated based on the culture media. Transplanted 
cells that have been pre-differentiated in vitro into the osteogenic lineage form bone-like 
tissues better than undifferentiated transplanted cells (Cowan, et al., 2005; Conjero, et al., 2006). 
Currently, there are two treatments that are being used in osteogenic differentiation, 
dexamethasone (DEX) and retinoic acid (RA) (Ogston et al., 2002). In addition, there are 
osteoinductive molecules that can be added to enhance bone formation such as bone 
morphogenic protein (BMP) and platelet derived growth factor. The exact intra-cellular 
mechanism through which these treatments stimulate osteogenic differentiation is unknown.  
4.1 Dexamethasone 
DEX is a synthetic glucocorticoid. Osteogenic differentiation occurs when stem cells are 
treated with DEX (Bielby et al., 2004; Pittenger, et al., 1999; C. Huang et al., 2009; Zuk, et al., 
2001; Young, et al., 2001), resulting in mineral deposits when grown in monolayer (Gronthos 
et al., 2000; Miura, et al., 2003; Seo, et al., 2004). However, the efficiency of the DEX 
treatment varies depending on the initial cell source (Chadipiralla, et al., 2010). The exact 
intra-cellular mechanism through which dexamethasone treatments stimulate osteogenic 
differentiation is unknown.  
4.2 Retinoic acid 
RA is an oxidized form of Vitamin A. RA was first used to up-regulate osteoblast 
differentiation and proliferation with great success (Song, et al., 2005; Kawaguchi et al., 2005; 
Skillington et al., 2002; Choong et al., 1993), then later used to induce osteogenic stem cell 
differentiation (Malladi et al., 2006; San Miguel, et al., 1998). The exact intra-cellular 
mechanism through which retinoic acid treatments stimulate osteogenic differentiation is 
unknown.  
4.3 Bone morphogenic protein 
BMP is a crucial protein in the osteoconductive process (Einhorn, 2003; Dimitriou, et al., 
2005; Kain & Einhorn, 2005; Govender, et al., 2002). There are many variations of BMP, each 
with its own functionality; BMP-2 and BMP-7 have been shown to be crucial for bone 
maintenance. BMP-2 and RA have been shown to accelerate bone formation and osteoclast 
recruitment in vivo (Cowan, et al., 2005). 
4.4 Platelet derived growth factor 
Bone platelet derived growth factor is a dose-dependent bone formation enhancer 
(Thorwarth et al., 2006).  
5. Scaffolds 
For regenerative tissue engineering, cells can be expanded and differentiated in monolayer 
but must be delivered to the body in a 3-D scaffold. When designing a 3-D scaffold, it is 
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important to take into account several key design elements such as the mechanical, 
chemical, and physiological properties of the scaffold, the environment it will be placed in, 
and the type of tissue it needs to support (Vacanti & Vacanti, 2000). The scaffold must have 
the correct surface chemistry and structure for optimizing the cell-scaffold interaction. In 
this case, the cells must be able to adhere to and proliferate on the scaffold. The scaffold 
must be biocompatible with the cells that it will support, in this case stem cells, and it must 
be biocompatible with the environment where it will eventually be placed in the body 
Additionally, the scaffold needs to have pores large enough for the cells to reside within it 
without being dislodged (pore size), and it needs to have well interconnected pores so 
nutrients can diffuse to the cells (porosity/interconnectivity). Mechanical strength is 
necessary for creating structurally sound replacement bone. However, the ideal scaffold 
would degrade as the new tissue formed. Many factors can cause polymers to break down 
through hydrolysis and enzymatic cleavage. Furthermore, some scaffolds are functionalized 
to release key agents in the healing cascade. Unfortunately, the ideal scaffold has not yet 
been identified, as a multitude of factors must be considered. The best scaffold for 
regenerative tissue engineering will vary depending on the type of injury, type of repair, 
and the final desired outcome. 
5.1 Extracellular matrix substitutes 
In-vivo, cells are suspended in a 3D scaffold called the extracellular matrix (ECM), which 
provides the cells with both the mechanical support and nutrients necessary for their survival. 
For optimal modeling of in-vivo conditions, scaffolds consisting of hydroxyapatite, naturally 
found in the ECM, have been investigated; unfortunately (Vial, 2008; Mastrogiacomo, et al., 
2005; Salgado et al., 2004), these scaffolds have low mechanical stability. 
5.2 Natural polymers 
Alternatively, natural polymers such as collagen, fibrinogen, chitosan, etc. have been 
investigated. Natural polymers are a popular choice, because they are biodegradable, 
bioactive, elicit a minimal immune response, and can be chemically versatile (Vial, 2008). 
Furthermore, researchers have shown that these polymers can be mineralized (Salgado et 
al., 2004), further mimicking the natural conditions of bone. Oftentimes, natural polymers 
can be formed by combining two components, thereby crosslinking the polymer to form a 
gel. In this case, the crosslinking agent and the cells could be injected into a bone healing site 
arthroscopically, thereby reducing the risk of infection from traditional open surgery.  
5.3 Synthetic polymers 
In addition, synthetic polymers can also be utilized to form a 3-D scaffold through various 
techniques such as fiber bonding, emulsion freeze drying, solvent casting/ particulate 
leaching, high-pressure processing, gas foaming/ particle leaching, thermally induced phase 
separation, electrospinning, and rapid prototyping (Chung & Park, 2007; Tsang & Bhatia, 
2004). Each is useful in forming a viable scaffold; however, the ideal scaffold must 
ultimately be selected based on the final desired outcome of the tissue repair. Ultimately, no 
synthetic manufactured scaffold is a perfect replacement for natural bone grafts.  
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5.4 Organ printing 
Organ printing is a branch of regenerative medicine in which 3D living tissues are 
constructed from single cells printed with a thermo-reversible gel. Mironov et al (Mironov et 
al., 2003) define organ printing as ‘a rapid prototyping computer-aided 3D printing 
technology, based on using layer by layer deposition of cell and/or cell aggregates into a 3D 
gel with sequential maturation of the printed construct into perfused and vascularized 
living tissue or organ.’ Organ printing takes place in 3 distinct phases: preprocessing, 
processing, and postprocessing. In preprocessing, a computer model of the tissue is 
constructed based on deficiencies observed via MRI or CT-scans. The processing is the 
actual layer by layer printing (placement) of cells in the 3D environment. The 
postprocessing consists of tissue perfusion, directing tissue maturation, and, finally 
biomechanical conditioning. If successful, organ printing may prove to be a valuable 
alternative form of regenerative medicine with a significantly decreased tissue maturation 
period compared to traditional tissue engineering approaches.  
6. In vitro studies of bone tissue engineering - bioreactor design 
It has been demonstrated that a combination of biochemical agents and mechanical forces 
can be used to accelerate the production of a desired phenotype (Freed, et al., 2006). 
Mechanotransduction refers to the biochemical cascade that converts a mechanical stimulus 
into chemical activity; in other words, the application of mechanical stress can guide stem 
cells to undergo guided differentiation (Haudenschild et al., 2009; Wang & Thampatty, 
2008). However, the application of mechanical stresses cannot be arbitrary, rather 
biomechanical models must be established to mimic in-vivo force patterns in an in-vitro 
bioreactor (Burdick & Vunjak-Novakovic, 2009; Butler, et al., 2008). The most important 
consideration in bioreactor design is mimicking in-vivo conditions, thereby mechanically 
conditioning tissue before it is transplanted into the body.  
6.1 Mechanical strain 
Bone specifically requires mechanical stimulation to maintain its strength. Astronauts who 
spend extended periods of time in space experience severe bone mineral loss due to the zero 
gravity conditions (Sikavitsas et al., 2001). Mechanical strain can be applied directly by 
compressing, stretching, or bending cell/scaffold constructs. Compressive bioreactors have 
been shown to increase both proteoglycan and matrix deposition by MSCs (Burger et al., 
1992; Wartella & Wayne, 2009). Uniaxial stretching of human osteoblastics cells has been 
shown to increase cell proliferation and increase gene expression of ALP, osteocalcin (OCN), 
osteopontin (OPN), and collagen type I (Col1) (Ignatius, et al., 2004; Ignatius, et al., 2005). 
On the other hand, cyclic stretching results in only increased proliferation (Neidlinger-Wilke 
et al., 1994). With MSCs, 4-point bending bioreactors can increase ALP activity levels, 
increase mineralized matrix production, and increase gene expression of ALP and OPN 
(Mauney, et al., 2004). 
6.2 Hydrodynamic shear stress 
In addition to mechanical stimulation, another important consideration is nutrient supply; 
cells placed in a bioreactor must have access to fresh nutrients from media, as well as a 
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means for removal of cellular waste (Rauh et al., 2011). Hydrodynamic shear stresses can 
be applied via spinner flask, rotation, or perfusion bioreactors: For spinner flask bioreactor 
systems, convective forces are applied by a stirrer which moves the media around the 
cell/scaffold construct. Studies using MSCs in spinner flasks have shown increased 
cellular proliferation, increased ALP activity levels, and increased gene expression of ALP, 
OPN, BSP, and Col1 (Kim H. , et al., 2007; Meinel, et al., 2004a; Mygind, et al., 2007; 
Stiehler, et al., 2009). Rotating bioreactor systems use laminar flow by rotating a vessel 
along the horizontal surface to create shear stress. Human ASCs and BM-MSCs have 
shown an increase in cellular proliferation and respective increases in ALP activity and 
OCN activity when cultured in rotating bioreactors (Diederichs, et al., 2009; Pound et al., 
2007). Furthermore, additional testing in rats also shows an increase in cellular 
distribution and extracellular matrix formation (Goldstein et al., 2001; Qiu et al., 1999). 
Finally, perfusion driven bioreactors address nutrient diffusion deficiencies by providing 
fresh media and creating fluid shear stress. Perfusion bioreactors increase cellular 
proliferation and distribution and cell viability in the center of cell/ scaffold constructs 
(Bernhardt et al., 2008; Frohlich, et al., 2010; Grayson, et al., 2008; Jagodzinski, et al., 2008; 
Meinel, et al., 2004b; Rauh et al., 2011).  
7. In vivo study of bone tissue engineering 
Currently, there is no consensus on the best clinical model for engineered bone tissue. 
Comparable to how transplanted cells that have been pre-differentiated in vitro form bone-
like tissues better than undifferentiated transplanted cells (Cowan, et al., 2005; Conjero, et 
al., 2006), engineered bone tissue that has been allowed to develop and mature in vitro 
promotes better bone healing after implantation than cell/ scaffold constructs that were not 
cultivated (Meinel, et al., 2004a; Meinel, et al., 2004b; Frohlich, et al., 2008). To assess the 
osteogenic potential of a cell/ scaffold construct, human cellular constructs were implanted 
subcutaneously in immunodeficient mice. Under these conditions, cells can develop into 
bone tissue in vivo (Kuznetsov, et al., 1997). Engineered bone tissue constructs have been 
used to repair load bearing and non-load bearing critical-size defects in various rodent 
models (Ohgushi et al., 1989; Puelacher et al., 1996; Bruder, et al., 1998a). Naturally critical-
sized defects exhibit incomplete repair due to limited number of autologous stem cells 
available for use in the repair process. Research on larger animal models such as sheep and 
dogs has shown repair of critical-sized defects was enhanced by the use of stem cells in 
engineered bone tissue (Bruder et al., 1998b; He, et al., 2007; Kon, et al., 2000; Petite, et al., 
2000; Shang, et al., 2001; Viateau, et al., 2007). 
8. Conclusions and future directions 
Regenerative tissue engineering addresses the discrepancy between the available 
transplantable donor tissue and the need. There are many choices for both cells and 
scaffolds, and the best combination will vary depending on the type of injury, type of repair, 
and the final desired outcome. Stem cells are an ideal cell source for bone regenerative tissue 
engineering applications, because they are capable of self- renewal, are undifferentiated, and 
can give rise to specialized tissue like bone. As our understanding of these cells improves, 
new engineering approaches (such as the 3D organ printer) will be developed to optimize 
the production of functional tissues.  
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